Does Omega-3 Polyunsaturated Fatty Acids (PUFAs) Pretreatment Improve Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI)?
Launched by SHIRAZ UNIVERSITY OF MEDICAL SCIENCES · Nov 5, 2012
Trial Information
Current as of May 17, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • candidate of elective PCI
- • Treatment with aspirin at least 5 days before PCI
- Exclusion Criteria:
- • high CKMB and troponin I level
- • cardiac bypass in recent 3 months
- • platelet count \< 70×10 9/L
- • sever chronic renal failure
- • active bleeding
- • treatment with glycoprotein IIb/IIIa inhibitors during PCI
- • treatment with bivalirudin during PCI
- • sensitivity to aspirin and clopidogrel
About Shiraz University Of Medical Sciences
Shiraz University of Medical Sciences (SUMS) is a leading academic institution in Iran dedicated to advancing healthcare through innovative research and education. As a prominent clinical trial sponsor, SUMS plays a pivotal role in conducting rigorous clinical studies aimed at improving medical practices and patient outcomes. The university is committed to fostering collaboration among healthcare professionals, researchers, and industry partners to translate scientific discoveries into effective therapies. With a focus on ethical standards and regulatory compliance, SUMS strives to contribute to the global body of medical knowledge while enhancing the quality of care within the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
farzaneh foroughinia, phD
Principal Investigator
Shiraz University of Medical Sciences
jamshid salamzadeh, phD
Principal Investigator
Shahid Beheshti University of Medical Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials